

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

HEL 92.1.7

RRID:CVCL_2481

Type: Cell Line

Proper Citation

RRID:CVCL_2481

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2481

Proper Citation: RRID:CVCL_2481

Description: Cell line HEL 92.1.7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Erythroleukemia

Defining Citation: [PMID:20215515](#), [PMID:22460905](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Donor information: Originally the patient was suffering from Hodgkin lymphoma., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEL 92.1.7

Synonyms: HEL92.1.7, HEL-92.1.7, HEL-92-1-7, HEL-92_1_7, HEL-92, HEL9217

Cross References: BTO:BTO_0003320, CLO:CLO_0003682, CLO:CLO_0003683, EFO:EFO_0002193, CLDB:cl5067, CLDB:cl7132, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:TIB-180, BCRC:60370, BCRJ:0308, BioSample:SAMN10987842, cancercellines:CVCL_2481, Cell_Model_Passport:SIDM00593, ChEMBL-Cells:ChEMBL4295457, ChEMBL-Targets:ChEMBL4296425, CLS:300462, Cosmic:683543, Cosmic:976723, DepMap:ACH-000005, ECACC:92111706, GEO:GSM887076, GEO:GSM888146, GEO:GSM1374526,

GEO:GSM1374527, IARC_TP53:21369, ICLC:HTL03002, IGRhCellID:HEL9217, LiGeA:CCLE_672, LINCS_LDP:LCL-1076, Lonza:1042, PharmacDB:HEL92_1_7_535_2019, Progenetix:CVCL_2481, PubChem_Cell_line:CVCL_2481, Wikidata:Q54882504

ID: CVCL_2481

Hierarchy: cvcl_0001

Record Creation Time: 20220427T220330+0000

Record Last Update: 20260815T233725+0000

Ratings and Alerts

No rating or validation information has been found for HEL 92.1.7.

No alerts have been found for HEL 92.1.7.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. Cell stem cell, 33(5), 800.

Roy P, et al. (2026) A stress-induced PI3P complex controls autophagy in erythroid precursors. iScience, 29(4), 115182.

Tripathi C, et al. (2026) Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. Cancer research communications, 6(3), 528.

Gao J, et al. (2026) Dual inhibition of tubulin and DNMT by the novel letermovir derivative H62 blocks leukemia. Biochemical pharmacology, 252, 118196.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.

Le BV, et al. (2026) Pol ϵ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. Cell reports. Medicine, 7(3), 102687.

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. Immunity, 58(2), 431.

Kumar S, et al. (2025) Development of PROTACs for targeted degradation of oncogenic TRK fusions. *bioRxiv : the preprint server for biology*.

Fiskus W, et al. (2025) Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. *Blood advances*, 9(21), 5598.

Liu T, et al. (2025) A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. *Cell reports*, 44(11), 116496.

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. *Blood*, 145(6), 612.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Saleiro D, et al. (2023) Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. *Cancer research communications*, 3(5), 943.

Blöchl C, et al. (2023) Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. *Cell & bioscience*, 13(1), 31.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Wei TT, et al. (2022) Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. *Cell*, 185(10), 1676.

Roversi FM, et al. (2022) Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. *Cancer immunology, immunotherapy : CII*, 71(8), 1909.

Yang BH, et al. (2022) Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine. *Frontiers in oncology*, 12, 809014.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular cell*, 81(17), 3604.